Metformin in Castration-Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Prospective Study of Metformin in Castration-Resistant Prostate Cancer

Status Terminated

Clinical Trial Summary

Metformin is a medication that is prescribed for people with diabetes to help the body respond better to its own insulin and decrease sugar production by the liver. This helps control the body's blood sugar level and is approved by the Food and Drug Administration (FDA) for the treatment of diabetes. Participant's in this research study will already be receiving androgen deprivation therapy (ADT) for prostate cancer. ADT is considered standard of care for prostate cancer. Changes in the participant's metabolism, including changes in insulin and blood sugar levels, are often seen as a result of this type of hormone therapy. Some studies have shown a relationship between insulin and prostate cancer. These studies have suggested that insulin may signal tumor cells to grow. Other studies suggest that people receiving metformin treatment for diabetes may enjoy better outcomes from their prostate cancer then other similar patients who are not treated with metformin.

Clinical Trial Description

• Each treatment cycle lasts 4 weeks (28 days). Participants will take metformin twice a day for all 28 days (except for the first 7 days of the first cycle when they will take it just once daily.)

• The following procedures will be done on Day 1 of treatment cycles 1, 2, 4, 7 and 10:

medical history review, performance status, physical exam, blood tests.

• If the participant's first computed tomography (CT) or bone scan at the time of screening showed evidence of cancer, CT and bone scans will be repeated on Day 1 of treatment cycles 4, 7 and 10.

• Participants will be in this research study for about 12 months. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT01215032
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Terminated
• Phase: N/A
• Start date: September 2010
• Completion date: January 2015